Thus enhanced acetylation of the p16 promoter while reducing p16 methylation, both contribute to the restoration of p16 gene expression, thereby affecting the expression of genes associated with cancer progression or repression that may be important targets for chemoprevention or therapy. Here, CDKN2A is linked to cancer.